Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 9;6(12):e506.
doi: 10.1038/bcj.2016.114.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

J R Jones  1   2 , D A Cairns  3 , W M Gregory  3 , C Collett  3 , C Pawlyn  1   2 , R Sigsworth  3 , A Striha  3 , R Henderson  3 , M F Kaiser  1   2 , M Jenner  4 , G Cook  5 , N H Russell  6 , C Williams  6 , G Pratt  7 , B Kishore  7 , J Lindsay  8 , M T Drayson  9 , F E Davies  1   10 , K D Boyd  2 , R G Owen  5 , G H Jackson  11 , G J Morgan  1   10
Affiliations
Clinical Trial

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial

J R Jones et al. Blood Cancer J. .

Abstract

We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95% confidence interval (CI) 0.4-1.0%), 2.3% (95% CI 1.6-2.7%) and 3.8% (95% CI 2.9-4.6%) at 1, 2 and 3 years, respectively. Patients receiving maintenance lenalidomide had a significantly higher SPM incidence overall (P=0.011). Age is a risk factor with the highest SPM incidence observed in transplant non-eligible patients aged >74 years receiving lenalidomide maintenance. The 3-year cumulative incidence in this group was 17.3% (95% CI 8.2-26.4%), compared with 6.5% (95% CI 0.2-12.9%) in observation only patients (P=0.049). There was a low overall incidence of haematological SPM (0.5%). The higher SPM incidence in patients receiving lenalidomide maintenance therapy, especially in advanced age, warrants ongoing monitoring although the benefit on survival is likely to outweigh risk.

PubMed Disclaimer

Conflict of interest statement

JRJ has received research and travel support from Celgene; WG: honoraria from Janssen and Celgene; CP: advisory board, honoraria and travel support from Celgene, Novartis and Takeda; MK: honoraria, consultancy, research funding and travel support from Celgene, BristolMyerSquibb (BMS), Chugia, Janssen and Takeda; MJ: honoraria from Takeda and Janssen; GC: consultancy and research funding from Janssen, Celgene, Takeda Oncology, Sanofi, Amgen and BMS; GP: Celgene Honoraria; BK: Celgene and Jazz Pharmaceuticals; FD: honoraria and travel support from Takeda-Milenium, Onyx-Amgen, Celgene and Janssen; KB: honoraria and travel support from Celgene and Janssen; RGO: honoraria and research funding from Celgene and Janssen; GHJ: honoraria from Celgene, Takeda and Amgen; GJM: honoraria, advisory committee, research funding; CancerNet, Multiple Myeloma Research Foundation, Celgene, Takeda-Millennium, BMS and Weisman Institute. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Consort diagram outlining the treatment pathway for all 104 SPMs confirmed as trial-related.
Figure 2
Figure 2
(a) Overall trial-related SPM incidence. The 1-, 2- and 3-year cumulative incidence of all SPM is 0.7%, 2.3% and 3.8% at 1, 2 and 3 years, respectively, for the whole trial. (b) Overall-trial related SPM incidence excluding NMSC. The 1-, 2- and 3-year cumulative incidence of all SPM when non-invasive malignancies are excluded is 0.6%, 1.8% and 2.9%, respectively, for the whole trial.
Figure 3
Figure 3
(a) TE pathway SPM incidence according to induction. Three-year SPM CI was 2.7% and 1.5% for the RCD and CTD induction groups, respectively; Fine and Gray P=0.014. n=756 RCD and 753 CTD. (b) TNE pathway SPM incidence according to induction. Three-year SPM CI was 5.9% and 5.9% for the RCDa and CTDa groups, respectively; Fine and Gray P=0.548. n=611 RCDa and 612 CTDa.
Figure 4
Figure 4
(a) Whole trial SPM incidence according to maintenance received. Three-year CI was 8.9% and 4.0% for the len and active observation maintenance groups, respectively; Fine and Gray P=0.011. n=820 len±vori and 540 active observation. (b) TE pathway SPM incidence according to maintenance received. Three-year CI was 5.8% and 2.0% for the len and active observation maintenance groups, respectively; Fine and Gray P=0.097. n=495 len±vori and 313 active observation. (c) TNE pathway SPM incidence according to maintenance received. Three-year CI was 12.9% and 6.3% for the len and active observation maintenance groups, respectively; Fine and Gray P=0.053. n=324 len±vori and 228 active observation. len, lenalidomide; vor, vorinostat.
Figure 5
Figure 5
(a) TNE patients >74 years old receiving maintenance. Overall 3-year CI was 17.3% and 6.5% for the len and active observation maintenance groups, respectively; P=0.049. n=144 len and 103 obs. (b) TNE patients ⩽74 years old receiving maintenance. Overall 3-year CI was 9.7% and 6.1% for the len and active observation maintenance groups, respectively; P=0.511. n=180 len and 125 obs. len, lenalidomide; obs, observation.
See this image and copyright information in PMC

References

    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520. - PMC - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122–1128. - PMC - PubMed
    1. Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011; 16: 1600–1603. - PMC - PubMed
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046–1060. - PubMed
    1. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164. - PubMed

Publication types

MeSH terms